Zdrowie i gospodarka · 21/09/2009

FDA Releases Guidance for Industry on End-of-Phase 2A Meetings

The Food and Drug Administration (FDA) has made available a guidance document titled 'End-of-Phase 2A Meetings' that provides information on end-of-phase 2A meetings for companies developing investigational new drug applications (INDs). The FDA aims to facilitate the development of innovative medical products through early meetings with sponsors to improve the quality of drug applications.